{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:14:49Z","timestamp":1788585289986,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jcjo.2026.04.020","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:35:56Z","timestamp":1782992156000},"page":"1191-1199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Screening for neurofibromatosis type 1-related optic pathway gliomas: a systematic review"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4405-3219","authenticated-orcid":false,"given":"Abdullrahman","family":"Alshehri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8434-3148","authenticated-orcid":false,"given":"Mohammed","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2506-9990","authenticated-orcid":false,"given":"Mishari","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Bin","family":"Mahfooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatim","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0252","authenticated-orcid":false,"given":"Sameh E.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.04.020_bib0001","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/CMAR.S362678","article-title":"Neurofibromatosis type 1-associated optic pathway gliomas: current challenges and future prospects","volume":"15","author":"Tang","year":"2023","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0002","first-page":"8","article-title":"An overview of optic pathway glioma with neurofibromatosis type 1: pathogenesis, risk factors, and therapeutic strategies","volume":"65","author":"Chen","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0003","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.3390\/cancers11111790","article-title":"Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations","volume":"11","author":"Cassina","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jpeds.2015.07.001","article-title":"The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1","volume":"167","author":"Prada","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejpn.2015.12.002","article-title":"Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort","volume":"20","author":"Blanchard","year":"2016","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0006","article-title":"Phenotype and genotype of Saudi pediatric patients with neurofibromatosis type 1: a seven-year multicenter experience from Saudi Arabia","volume":"15","author":"Alfurayh","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0007","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2147\/JMDH.S454921","article-title":"Epidemiology and outcomes of neurofibromatosis type 1 (NF-1): multicenter tertiary experience","volume":"17","author":"Almuqbil","year":"2024","journal-title":"J Multidiscip Healthc"},{"issue":"Suppl 1","key":"10.1016\/j.jcjo.2026.04.020_bib0008","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/WNO.0000000000000550","article-title":"Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision","volume":"37","author":"de Blank","year":"2017","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1","volume":"56","author":"Carton","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","article-title":"Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966","volume":"15","author":"Bergqvist","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0011","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s40246-024-00700-x","article-title":"Nationwide survey on awareness of consanguinity and genetic diseases in Saudi Arabia: challenges and potential solutions to reduce the national healthcare burden","volume":"18","author":"Yousef","year":"2024","journal-title":"Hum Genomics"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0012","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jiph.2019.06.001","article-title":"National screening programs in Saudi Arabia: overview, outcomes, and effectiveness","volume":"12","author":"Gosadi","year":"2019","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0013","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13023-021-02121-8","article-title":"Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study","volume":"16","author":"Henning","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0014","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.ophtha.2011.12.035","article-title":"Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas","volume":"119","author":"Kelly","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0016","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0017","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archneurpsyc.1958.02340060003001","article-title":"Gliomas of the optic nerves","volume":"79","author":"Dodge","year":"1958","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0018","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0019","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajmg.a.20211","article-title":"Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome","volume":"122A","author":"King","year":"2003","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0021","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0887-8994(02)00628-8","article-title":"Long-term outcome in children with gliomas of the anterior visual pathway","volume":"28","author":"Tow","year":"2003","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0022","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1215\/15228517-2007-031","article-title":"Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program","volume":"9","author":"Dalla Via","year":"2007","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0023","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3389\/fneur.2018.01102","article-title":"Use of optical coherence tomography to detect retinal nerve fiber loss in children with optic pathway glioma","volume":"9","author":"Zahavi","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0024","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/neuonc\/nos076","article-title":"Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis","volume":"14","author":"Fisher","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0025","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41433-022-02096-1","article-title":"Visual outcomes and predictors in optic pathway glioma: a single centre study","volume":"37","author":"Bowman","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0026","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ophtha.2003.06.008","article-title":"Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients","volume":"111","author":"Thiagalingam","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0027","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3928\/01913913-20160810-03","article-title":"Optic gliomas in neurofibromatosis type 1","volume":"53","author":"Parkhurst","year":"2016","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0028","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaapos.2006.03.014","article-title":"Orbital optic nerve gliomas in children with neurofibromatosis type 1","volume":"10","author":"Zeid","year":"2006","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0029","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11060-017-2517-6","article-title":"Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1","volume":"134","author":"Trevisson","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaapos.2009.11.020","article-title":"Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients","volume":"14","author":"Segal","year":"2010","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0031","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/08830738030180070401","article-title":"Optic pathway gliomas in children with and without neurofibromatosis 1","volume":"18","author":"Czyzyk","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0032","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jaapos.2006.02.004","article-title":"Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?","volume":"10","author":"Wolsey","year":"2006","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0033","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ejpn.2015.03.002","article-title":"Comparative study of the ophthalmological examinations in neurofibromatosis type 1. Proposal for a new screening algorithm","volume":"19","author":"Caen","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0034","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/neuonc\/noaa153","article-title":"NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat","volume":"23","author":"Azizi","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaapos.2015.06.003","article-title":"Strabismus in patients with neurofibromatosis type 1-associated optic pathway glioma","volume":"19","author":"Parness-Yossifon","year":"2015","journal-title":"J AAPOS"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0036","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713481","article-title":"Insights into novel choroidal and retinal clinical signs in neurofibromatosis type 1","volume":"24","author":"Mallone","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0038","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13023-022-02369-8","article-title":"An update on choroidal abnormalities and retinal microvascular changes in neurofibromatosis type 1","volume":"17","author":"Mallone","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0039","first-page":"1","article-title":"Choroidal abnormalities in neurofibromatosis type 1","author":"ElMeshad","year":"2026","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.oret.2024.11.012","article-title":"Yasunari nodules: a diagnostic criterion for neurofibromatosis type 1","volume":"9","author":"G\u00f3mez-Benlloch","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0041","first-page":"129","article-title":"Neurofibromatosis type 1-associated gliomas and other tumors: A new pathway forward?","volume":"8","author":"Carrion","year":"2023","journal-title":"Ped Hematol Oncol J"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0042","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2147\/CMAR.S362678","article-title":"Neurofibromatosis type 1-associated optic pathway gliomas: current challenges and future prospects","volume":"15","author":"Tang","year":"2023","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0043","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-24-1611","article-title":"Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis type 1, Noonan syndrome, CBL syndrome, Costello syndrome, and related RASopathies","volume":"30","author":"Perrino","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.908573","article-title":"Current update on the visual outcome of optic pathway glioma associated with neurofibromatosis type-1","volume":"9","author":"Zeid","year":"2022","journal-title":"Front Surg"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2020.03.053","article-title":"Neurofibromatosis type 1-associated optic pathway glioma in children: a follow-up of 10 years or more","volume":"221","author":"Kinori","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.17427","article-title":"Anesthetic exposure during childhood and neurodevelopmental outcomes: a systematic review and meta-analysis","volume":"5","author":"Reighard","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0047","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/COC.0b013e3182467efa","article-title":"Optic glioma in children: a retrospective analysis of 101 cases","volume":"36","author":"Varan","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0048","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/WNO.0b013e31822aef82","article-title":"Optic pathway gliomas","volume":"31","author":"Avery","year":"2011","journal-title":"J Neuroophthalmol"},{"issue":"21 Suppl 1","key":"10.1016\/j.jcjo.2026.04.020_bib0049","first-page":"S15","article-title":"Functional outcome measures for NF1-associated optic pathway glioma clinical trials","volume":"81","author":"Fisher","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.spen.2017.04.006","article-title":"Optic pathway gliomas secondary to neurofibromatosis type 1","volume":"24","author":"Beres","year":"2017","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0051","first-page":"1","article-title":"Automatic visual acuity loss prediction in children with optic pathway gliomas using magnetic resonance imaging","volume":"2023","author":"Jiang","year":"2023","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0052","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1212\/WNL.0000000000003402","article-title":"Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1","volume":"87","author":"Avery","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jcjo.2026.04.020_bib0053","first-page":"vdaa090","article-title":"Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning","volume":"2","author":"Pisapia","year":"2020","journal-title":"Neurooncol Adv"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:25:41Z","timestamp":1788582341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418226001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0008418226001572"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.04.020","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening for neurofibromatosis type 1-related optic pathway gliomas: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}